The Life Sciences team represented Aditum Bio on the launch of Kalexo Bio, a new company formed in conjunction with an exclusive global license agreement with Mabwell Bioscience for the development of 2MW7141, a novel dual-target siRNA candidate for lipid management in patients with dyslipidemia and for the prevention of high-risk atherosclerotic cardiovascular disease (ASCVD) events. Aditum Bio will provide funding for Kalexo Bio, and the parties will collaborate to advance 2MW7141 into clinical development.
Goodwin advised Kalexo Bio on its exclusive global license agreement with Mabwell, under which Kalexo Bio is granted exclusive worldwide rights to develop, manufacture, and commercialize 2MW7141. Mabwell is eligible to receive a total of up to USD $1 billion in upfront and milestone payments, as well as tiered royalties on global sales. This includes $12 million in non-refundable upfront and near-term cash payments. Mabwell will also receive an equity stake in Kalexo Bio.
Aditum Bio is a biotech venture firm committed to improving health by accelerating drug development in disease areas with high unmet need where medical innovation can have a significant impact. Aditum Bio in-licenses promising drug candidates and spins out individual companies dedicated to bringing each candidate through early clinical trials.
The Goodwin team was led by Rachael Bushey, Shannyn Henke, Adam Dilluvio, Connor McMillan, and Julia Novick and included Daniel Scolnick, Madison Clausius, Dan Karelitz, and Erika Pey.
For more information on the deal, please read the press release.